Cargando…

Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China

Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yi, Xu, Ting, Yuan, Lin, Zhang, Lin, Ruan, Xinjia, Wu, Shan, Meng, Huangyang, Cheng, Wenjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101289/
https://www.ncbi.nlm.nih.gov/pubmed/37058057
http://dx.doi.org/10.1097/MD.0000000000033434
_version_ 1785025478208258048
author Jiang, Yi
Xu, Ting
Yuan, Lin
Zhang, Lin
Ruan, Xinjia
Wu, Shan
Meng, Huangyang
Cheng, Wenjun
author_facet Jiang, Yi
Xu, Ting
Yuan, Lin
Zhang, Lin
Ruan, Xinjia
Wu, Shan
Meng, Huangyang
Cheng, Wenjun
author_sort Jiang, Yi
collection PubMed
description Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of China. The study included 98 patients who received Olaparib and 210 patients without Olaparib from July 2018 to October 2021 for high-grade serous ovarian cancer in the Gynecology Oncology Department of Jiangsu Provincial Hospital. Information of clinicopathologic characteristics was collected from medical records. Then, we used the QLQ-C30 and Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) to determine the QoL of 98 patients with and 210 patients without Olaparib. Among all 98 patients with Olaparib, 66 patients in first-line and 32 patients in more than second-line treatment. Regarding the best objective response with Olaparib maintenance in 78 patients with partial remission from most recent chemotherapy, 3 (3.84%) patients showed complete response (CR) and 6 (7.69%) showed as partial response (PR), whereas stable disease was observed in 42 patients (53.84%) and 27 patients (34.6%) showed as progression disease. AEs of Grade 3 and more were: anemia in 16 patients (16.32%), neutropenia in 20 patients (20.40%), thrombocytopenia in 4 patients (4.08%), and headache in 4 patients (4.08%). Dose reduction and drug discontinuation accounted for 73.40% and 20.40%, respectively. Olaparib as maintenance therapy increased QoL on all functioning domains and several symptom domains. Consistent with previous clinical trials, Olaparib maintenance therapy was proved safe and effective. Most patients may experience Grade 1 and 2 AEs. Olaparib maintenance therapy can increase QoL in several domains.
format Online
Article
Text
id pubmed-10101289
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-101012892023-04-14 Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China Jiang, Yi Xu, Ting Yuan, Lin Zhang, Lin Ruan, Xinjia Wu, Shan Meng, Huangyang Cheng, Wenjun Medicine (Baltimore) 5600 Olaparib showed good efficacy and tolerability in the maintenance treatment of patients with initial therapy or high-grade serous recurrent ovarian cancer patients. This study aimed to analyze adverse events (AEs) of patients taking Olaparib and the quality of life (QoL) with Olaparib in 1 center of China. The study included 98 patients who received Olaparib and 210 patients without Olaparib from July 2018 to October 2021 for high-grade serous ovarian cancer in the Gynecology Oncology Department of Jiangsu Provincial Hospital. Information of clinicopathologic characteristics was collected from medical records. Then, we used the QLQ-C30 and Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) to determine the QoL of 98 patients with and 210 patients without Olaparib. Among all 98 patients with Olaparib, 66 patients in first-line and 32 patients in more than second-line treatment. Regarding the best objective response with Olaparib maintenance in 78 patients with partial remission from most recent chemotherapy, 3 (3.84%) patients showed complete response (CR) and 6 (7.69%) showed as partial response (PR), whereas stable disease was observed in 42 patients (53.84%) and 27 patients (34.6%) showed as progression disease. AEs of Grade 3 and more were: anemia in 16 patients (16.32%), neutropenia in 20 patients (20.40%), thrombocytopenia in 4 patients (4.08%), and headache in 4 patients (4.08%). Dose reduction and drug discontinuation accounted for 73.40% and 20.40%, respectively. Olaparib as maintenance therapy increased QoL on all functioning domains and several symptom domains. Consistent with previous clinical trials, Olaparib maintenance therapy was proved safe and effective. Most patients may experience Grade 1 and 2 AEs. Olaparib maintenance therapy can increase QoL in several domains. Lippincott Williams & Wilkins 2023-04-14 /pmc/articles/PMC10101289/ /pubmed/37058057 http://dx.doi.org/10.1097/MD.0000000000033434 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 5600
Jiang, Yi
Xu, Ting
Yuan, Lin
Zhang, Lin
Ruan, Xinjia
Wu, Shan
Meng, Huangyang
Cheng, Wenjun
Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title_full Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title_fullStr Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title_full_unstemmed Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title_short Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China
title_sort analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with olaparib maintenance therapy: a single-center study in china
topic 5600
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101289/
https://www.ncbi.nlm.nih.gov/pubmed/37058057
http://dx.doi.org/10.1097/MD.0000000000033434
work_keys_str_mv AT jiangyi analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT xuting analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT yuanlin analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT zhanglin analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT ruanxinjia analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT wushan analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT menghuangyang analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina
AT chengwenjun analysisofadverseeventsandqualityoflifeinhighgradeserousovariancancerpatientswitholaparibmaintenancetherapyasinglecenterstudyinchina